237 results on '"Hogan, William J."'
Search Results
2. The MAGIC algorithm probability predicts treatment response and long-term outcomes to second-line therapy for acute GVHD
3. Amphiregulin, ST2, and REG3α biomarker risk algorithms as predictors of nonrelapse mortality in patients with acute GVHD
4. Flares of acute graft-versus-host disease: a Mount Sinai Acute GVHD International Consortium analysis
5. A Day 14 Endpoint for Acute GVHD Clinical Trials
6. Phase 2 study of natalizumab plus standard corticosteroid treatment for high-risk acute graft-versus-host disease
7. Incidence, clinical presentation, risk factors, outcomes, and biomarkers in de novo late acute GVHD
8. Effective treatment of low-risk acute GVHD with itacitinib monotherapy
9. Relationship of iothalamate clearance and NRM in patients receiving fludarabine and melphalan reduced-intensity conditioning
10. A Validated Risk Stratification That Incorporates MAGIC Biomarkers Predicts Long-Term Outcomes in Pediatric Patients with Acute GVHD
11. Assessment of systemic and gastrointestinal tissue damage biomarkers for GVHD risk stratification
12. Biomarker-guided preemption of steroid-refractory graft-versus-host disease with α-1-antitrypsin
13. Bone marrow dendritic cell aggregates associate with systemic immune dysregulation in chronic myelomonocytic leukemia
14. Prognostic Role of Beta-2 Microglobulin in Patients with Light Chain Amyloidosis Treated with Autologous Stem Cell Transplantation
15. Subsequent neoplasms and late mortality in children undergoing allogeneic transplantation for nonmalignant diseases
16. Comparison of Pretransplantation Prediction Models for Nonrelapse Mortality in Patients with Myelofibrosis Undergoing Allogeneic Stem Cell Transplantation
17. Pericardial Effusion as a Purported Manifestation of Graft-versus-Host Disease following Allogeneic Hematopoietic Cell Transplantation
18. The MAGIC algorithm probability is a validated response biomarker of treatment of acute graft-versus-host disease
19. Allogeneic Hematopoietic Stem Cell Transplantation in the Outpatient Setting: The Mayo Clinic Experience
20. Risk Factors and Outcomes of Nocardiosis in Hematopoietic Stem Cell Transplantation Recipients
21. Outcomes of Patients with Light Chain Amyloidosis Who Had Autologous Stem Cell Transplantation with 3 or More Organs Involved
22. Utilization and Outcomes of Fertility Preservation Techniques in Women Undergoing Allogeneic Hematopoietic Cell Transplant
23. Extracorporeal Photopheresis Improves Survival in Hematopoietic Cell Transplant Patients with Bronchiolitis Obliterans Syndrome without Significantly Impacting Measured Pulmonary Functions
24. MAGIC biomarkers predict long-term outcomes for steroid-resistant acute GVHD
25. Genetic features and outcomes of allogeneic transplantation in patients with WT1-mutated myeloid neoplasms
26. The MAGIC Algorithm Probability Predicts Treatment Response and Long-Term Outcomes to Second-Line Therapy for Acute Gvhd
27. Experience With an Optical Character Recognition Search Application for Review of Outside Medical Records
28. Safety and Efficacy of Infliximab Therapy in the Setting of Steroid-Refractory Acute Graft-versus-Host Disease
29. Impact of Post-Transplant Response and Minimal Residual Disease on Survival in Myeloma with High-Risk Cytogenetics
30. Second Stem Cell Transplantation for Relapsed Refractory Light Chain (AL) Amyloidosis
31. Azithromycin for the Treatment of Obliterative Bronchiolitis after Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis
32. Late acute graft-versus-host disease: a prospective analysis of clinical outcomes and circulating angiogenic factors
33. Impact of Novel Targeted Therapies and Cytogenetic Risk Groups on Outcome After Allogeneic Transplantation for Adult ALL
34. Medical Students' Knowledge, Familiarity, and Attitudes towards Hematopoietic Stem Cell Donation: Stem Cell Donation Behaviors
35. Employment Status as an Indicator of Recovery and Function One Year after Hematopoietic Stem Cell Transplantation
36. Metabolic Syndrome and Cardiovascular Disease after Hematopoietic Cell Transplantation: Screening and Preventive Practice Recommendations from the CIBMTR and EBMT
37. Fludarabine-Busulfan Reduced-Intensity Conditioning in Comparison with Fludarabine-Melphalan Is Associated with Increased Relapse Risk In Spite of Pharmacokinetic Dosing
38. The Incidence and Severity of Oral Mucositis among Allogeneic Hematopoietic Stem Cell Transplantation Patients: A Systematic Review
39. International, Multicenter Standardization of Acute Graft-versus-Host Disease Clinical Data Collection: A Report from the Mount Sinai Acute GVHD International Consortium
40. The utility of biomarkers in acute GVHD prognostication
41. Long-Term Pulmonary Function Trajectories After Allogeneic Bone Marrow Transplantation
42. Impact of Alemtuzumab Therapy and Route of Administration in T-Prolymphocytic Leukemia: A Single-Center Experience
43. Monosomal Karyotype Predicts Adverse Prognosis in Patients Diagnosed With Chronic Myelomonocytic Leukemia: A Single-Institution Experience
44. Clinical and prognostic impact of STAG2 mutations in myeloid neoplasms: the Mayo Clinic experience
45. Infused Autograft Lymphocyte to Monocyte Ratio and Survival in Diffuse Large B Cell Lymphoma
46. Response Rates to Venetoclax Based Therapies in Chronic Phase and Blast Transformed Chronic Myelomonocytic Leukemia
47. Effective Treatment of Low Risk Acute Gvhd with Itacitinib Monotherapy
48. Cardiac events in patients with acute myeloid leukemia treated with venetoclax combined with hypomethylating agents
49. Incidence of Supraventricular Arrhythmias during Autologous Peripheral Blood Stem Cell Transplantation
50. Cost-Effectiveness Analysis of a Risk-Adapted Algorithm of Plerixafor Use for Autologous Peripheral Blood Stem Cell Mobilization
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.